What is the share price of Parnax Lab Ltd (PARNAXLAB) today?
The share price of PARNAXLAB as on 22nd October 2026 is ₹104.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Parnax Lab Ltd (PARNAXLAB) share?
The past returns of Parnax Lab Ltd (PARNAXLAB) share are- Past 1 week: -6.35%
- Past 1 month: -12.13%
- Past 3 months: -27.97%
- Past 6 months: -34.97%
- Past 1 year: -19.37%
- Past 3 years: 15.10%
- Past 5 years: 301.74%
What are the peers or stocks similar to Parnax Lab Ltd (PARNAXLAB)?
The peers or stocks similar to Parnax Lab Ltd (PARNAXLAB) include:What is the market cap of Parnax Lab Ltd (PARNAXLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Parnax Lab Ltd (PARNAXLAB) is ₹148.57 Cr as of 22nd October 2026.What is the 52 week high and low of Parnax Lab Ltd (PARNAXLAB) share?
The 52-week high of Parnax Lab Ltd (PARNAXLAB) is ₹182 and the 52-week low is ₹99.20.What is the PE and PB ratio of Parnax Lab Ltd (PARNAXLAB) stock?
The P/E (price-to-earnings) ratio of Parnax Lab Ltd (PARNAXLAB) is 12.62. The P/B (price-to-book) ratio is 1.56.Which sector does Parnax Lab Ltd (PARNAXLAB) belong to?
Parnax Lab Ltd (PARNAXLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Parnax Lab Ltd (PARNAXLAB) shares?
You can directly buy Parnax Lab Ltd (PARNAXLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Parnax Lab Ltd
PARNAXLAB Share Price
NSE₹104.050.11% (+0.11)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP
PARNAXLAB Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PARNAXLAB Performance & Key Metrics
PARNAXLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 16.58 | 1.56 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.18 | 5.54 | 0.51% |
PARNAXLAB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PARNAXLAB Company Profile
Parnax Lab is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations
PE Ratio
36.76
36.76
1Y Return
4.03%
4.03%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
80.16
80.16
1Y Return
27.70%
27.70%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.23
22.23
1Y Return
12.49%
12.49%
Buy Reco %
57.69
57.69
LAURUSLABS
PE Ratio
125.24
125.24
1Y Return
114.31%
114.31%
Buy Reco %
61.54
61.54
CIPLA
PE Ratio
27.60
27.60
1Y Return
19.10%
19.10%
Buy Reco %
62.86
62.86
PARNAXLAB Forecast
PARNAXLAB Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PARNAXLAB
PARNAXLAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
PARNAXLAB Income Statement
PARNAXLAB Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 46.62 | 50.23 | 49.31 | 40.41 | 49.46 | 53.56 | 63.23 | 63.91 | 71.62 | 56.96 | ||||||||||
Operating & Other expenses | 40.57 | 41.50 | 41.12 | 35.94 | 42.41 | 45.94 | 54.52 | 57.23 | 64.97 | 52.50 | ||||||||||
EBITDA | 6.05 | 8.73 | 8.19 | 4.47 | 7.05 | 7.62 | 8.71 | 6.68 | 6.65 | 4.46 | ||||||||||
| Depreciation/Amortization | 1.84 | 1.83 | 1.94 | 1.79 | 1.83 | 1.94 | 2.10 | 1.96 | 2.04 | 2.22 | ||||||||||
| PBIT | 4.21 | 6.90 | 6.25 | 2.68 | 5.22 | 5.68 | 6.61 | 4.72 | 4.61 | 2.24 | ||||||||||
| Interest & Other Items | 1.41 | 1.50 | 1.38 | 1.23 | 1.28 | 1.22 | 1.40 | 1.47 | 1.61 | 1.64 | ||||||||||
| PBT | 2.80 | 5.40 | 4.87 | 1.45 | 3.94 | 4.46 | 5.21 | 3.25 | 3.00 | 0.60 | ||||||||||
| Taxes & Other Items | 0.54 | 1.43 | 1.46 | 0.24 | 1.04 | 1.19 | 1.57 | 0.54 | 0.82 | 0.17 | ||||||||||
| Net Income | 2.26 | 3.97 | 3.41 | 1.21 | 2.90 | 3.27 | 3.64 | 2.71 | 2.18 | 0.43 | ||||||||||
| EPS | 1.95 | 3.47 | 2.97 | 1.06 | 2.55 | 2.85 | 3.15 | 2.37 | 1.90 | 0.37 |
PARNAXLAB Company Updates
PARNAXLAB Stock Peers
PARNAXLAB Past Performance & Peer Comparison
PARNAXLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Parnax Lab Ltd | 12.62 | 1.56 | — |
| Sun Pharmaceutical Industries Limited | 36.76 | 5.03 | 0.91% |
| Torrent Pharmaceuticals Ltd | 80.16 | 9.86 | 0.74% |
| Zydus Lifesciences Ltd | 22.23 | 3.79 | 0.09% |
Compare valuation on ScreenerPARNAXLAB Stock Price Comparison
Compare PARNAXLAB with any stock or ETFCompare PARNAXLAB with any stock or ETF
PARNAXLAB
PARNAXLAB Holdings
PARNAXLAB Shareholdings
PARNAXLAB Promoter Holdings Trend
PARNAXLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
PARNAXLAB Institutional Holdings Trend
PARNAXLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PARNAXLAB Shareholding Pattern
PARNAXLAB Shareholding Pattern
PARNAXLAB Shareholding History
PARNAXLAB Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing PARNAXLAB stock
smallcases containing PARNAXLAB stock
Looks like this stock is not in any smallcase yet.
PARNAXLAB Events
PARNAXLAB Events
PARNAXLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PARNAXLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PARNAXLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PARNAXLAB has not given any dividends in last 5 years
PARNAXLAB Dividends
PARNAXLAB Dividends
Hmm, looks like data is unavailable here. Please come back after some timePARNAXLAB Stock News & Opinions
PARNAXLAB Stock News & Opinions
Articles & Videos
Earnings
Earnings
Parnax Lab Ltd consolidated sales down 18.43% on year in Q2FY2026, net profit witnessed a sharp fall of 80.28%Parnax Lab Ltd share price inched up 1.56% to Rs 133.05. The Company's net profit tumbled by 80.28% to Rs 0.43 crore, while revenue from operations reduced 18.43% to Rs 56.8 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.63%. It has marginally improved by 0.66% over last one week and advanced by 11.20% in last one month while the market capitalization of Parnax Lab Ltd has slipped by 0.97% and 17.74% in the same period respectively. Profit before tax (PBT) of Parnax Lab Ltd stood at Rs 0.6 crore in Q2 FY26, tanking 86.55% year-on-year, and crashing by 80.00% quarter-on-quarter. EBITDA came in at Rs 4 crore, nosediving by 42.76% YoY and expanding by 43.10% sequentially. Total expenses reduced by 18.06% to Rs 54.72 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 33.44 crore, tumbling by 23.58% YoY, while employee benefits expense was at Rs 7.82 crore, rising by 8.61% YoY. For the TTM ended FY26, revenue from operations declined slightly by 0.51% to Rs 187.74 crore, while net profit rose by 19.96% to Rs 11.54 crore, compared to previous TTM. EBITDA jumped by 2214% to Rs 25.09 crore, and PBT jumped 30.04% to Rs 15.67 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 32.3 crore in FY26, as against Rs 15.88 crore in FY25. Parnax Lab Ltd ticked higher by 2.35% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.05% during the same period.
2 months agoCapital Market - Live
Corporate
Corporate
Parnax Lab schedules board meetingParnax Lab will hold a meeting of the Board of Directors of the Company on 28 May 2026.
5 months agoCapital Market - Live
Earnings
Earnings
Parnax Lab consolidated net profit rises 123.97% in the December 2025 quarterNet profit of Parnax Lab rose 123.97% to Rs 2.71 crore in the quarter ended December 2025 as against Rs 1.21 crore during the previous quarter ended December 2024. Sales rose 56.49% to Rs 62.94 crore in the quarter ended December 2025 as against Rs 40.22 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales62.9440.22 56 OPM %10.8810.62 - PBDT6.353.23 97 PBT4.391.45 203 NP2.711.21 124 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Parnax Lab to hold board meetingParnax Lab will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Earnings
Parnax Lab consolidated net profit rises 6.45% in the September 2025 quarterNet profit of Parnax Lab rose 6.45% to Rs 3.63 crore in the quarter ended September 2025 as against Rs 3.41 crore during the previous quarter ended September 2024. Sales rose 29.45% to Rs 62.60 crore in the quarter ended September 2025 as against Rs 48.36 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales62.6048.36 29 OPM %12.9114.97 - PBDT7.316.81 7 PBT5.204.87 7 NP3.633.41 6 Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Corporate
Parnax Lab to conduct board meetingParnax Lab will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Corporate
Parnax Lab to hold AGMParnax Lab announced that the 43th Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Earnings
Earnings
Parnax Lab consolidated net profit declines 17.84% in the June 2025 quarterNet profit of Parnax Lab declined 17.84% to Rs 3.27 crore in the quarter ended June 2025 as against Rs 3.98 crore during the previous quarter ended June 2024. Sales rose 6.50% to Rs 53.38 crore in the quarter ended June 2025 as against Rs 50.12 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales53.3850.12 7 OPM %13.9417.20 - PBDT6.407.23 -11 PBT4.465.40 -17 NP3.273.98 -18 Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Corporate
Parnax Lab to discuss resultsParnax Lab will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Earnings
Earnings
Parnax Lab consolidated net profit rises 30.36% in the March 2025 quarterNet profit of Parnax Lab rose 30.36% to Rs 2.92 crore in the quarter ended March 2025 as against Rs 2.24 crore during the previous quarter ended March 2024. Sales rose 5.76% to Rs 49.04 crore in the quarter ended March 2025 as against Rs 46.37 crore during the previous quarter ended March 2024. For the full year,net profit rose 19.88% to Rs 11.52 crore in the year ended March 2025 as against Rs 9.61 crore during the previous year ended March 2024. Sales declined 0.51% to Rs 187.74 crore in the year ended March 2025 as against Rs 188.71 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales49.0446.37 6 187.74188.71 -1 OPM %13.5212.49 -14.2512.47 - PBDT5.784.63 25 23.0519.01 21 PBT3.952.79 42 15.6712.05 30 NP2.922.24 30 11.529.61 20 Powered by Capital Market - Live
1 year agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 22.82%, vs industry avg of 11.75%
Over the last 5 years, market share increased from 0.03% to 0.05%